包裹性腹膜硬化症的发病机制及防治  

Pathogenesis and management of encapsulating peritoneal sclerosis in peritoneal dialysis

作　　者：周玉超[1] 俞雨生[1] 

机构地区：[1]南京军区南京总医院肾脏科国家肾脏疾病临床医学研究中心全军肾脏病研究所,南京210016

出　　处：《肾脏病与透析肾移植杂志》2015年第6期573-577,共5页Chinese Journal of Nephrology,Dialysis & Transplantation

摘　　要：包裹性腹膜硬化症(EPS)是由于腹膜广泛增厚黏连导致持续或反复出现肠梗阻的一组临床综合征。EPS是长期腹膜透析(PD)患者中一种少见但严重的并发症。腹膜炎症、新生血管形成及纤维化是形成EPS的关键步骤,腹膜纤维化和黏连是EPS的核心。目前EPS的发病机制尚未完全明确,仍然缺乏理想的治疗手段。本文将对EPS发病机制及防治研究进展做一综述。Encapsulating peritoneal sclerosis （ EPS） has been defined as a clinical syndrome continuously, intermittently, or repeatedly presenting with symptoms of intestinal obstruction due to adhesions of a diffusely thickened peritoneum. EPS is a serious complication that can occur during long-term peritoneal dialysis （ PD） , although only a small percentage of PD patients develop EPS. Inflammation, angiogenesis, and fibrosis of the peritoneum are the key factors while peritoneal fibrosis and adhesion is the core element. The precise mechanism underlying EPS remains unclear and the optimal management regime for EPS is yet to be established. New research progresses on pathogenesis and preventive/therapeutic strategies of EPS will be presented in this review.

关 键 词：包裹性腹膜硬化症 腹膜纤维化 腹膜透析 

分 类 号：R459.5[医药卫生—治疗学]